DE60113645D1 - Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten - Google Patents

Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten

Info

Publication number
DE60113645D1
DE60113645D1 DE60113645T DE60113645T DE60113645D1 DE 60113645 D1 DE60113645 D1 DE 60113645D1 DE 60113645 T DE60113645 T DE 60113645T DE 60113645 T DE60113645 T DE 60113645T DE 60113645 D1 DE60113645 D1 DE 60113645D1
Authority
DE
Germany
Prior art keywords
inhibitor
treatment
histone deacetylase
hpv16
hdac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60113645T
Other languages
English (en)
Other versions
DE60113645T2 (de
Inventor
Patrick Finzer
Hausen Harald Zur
Frank Roesl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of DE60113645D1 publication Critical patent/DE60113645D1/de
Publication of DE60113645T2 publication Critical patent/DE60113645T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60113645T 2001-04-10 2001-04-10 Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten Expired - Fee Related DE60113645T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01108923A EP1249246B1 (de) 2001-04-10 2001-04-10 Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten

Publications (2)

Publication Number Publication Date
DE60113645D1 true DE60113645D1 (de) 2006-02-09
DE60113645T2 DE60113645T2 (de) 2006-07-06

Family

ID=8177103

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60113645T Expired - Fee Related DE60113645T2 (de) 2001-04-10 2001-04-10 Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten

Country Status (5)

Country Link
US (1) US20040132817A1 (de)
EP (1) EP1249246B1 (de)
AT (1) ATE305297T1 (de)
DE (1) DE60113645T2 (de)
WO (1) WO2002083173A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1291015A1 (de) 2001-09-10 2003-03-12 Lunamed AG Darreichungsformen mit verlängerter Wirkstofffreisetzung
ES2342378T3 (es) * 2002-08-20 2010-07-06 Astellas Pharma Inc. Inhibidor de degradacion de matriz extracelular del cartilago artrodial.
US20050222013A1 (en) * 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
CA2574531C (en) * 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
CN101959429B (zh) 2008-01-08 2014-09-10 阿克塞利亚制药公司 抗微生物肽系统的激动剂
US20120269818A1 (en) * 2011-04-25 2012-10-25 Ozbun Michelle A Methods for treating infection by hpv
WO2014138507A1 (en) * 2013-03-06 2014-09-12 C & C Biopharma, Llc Treatment of cervical cancer and/or ovarian cancer using a transcription factor modulator
US10307406B2 (en) * 2013-08-31 2019-06-04 The Wistar Institute Of Anatomy And Biology Methods and compositions for re-activating Epstein-Barr virus and screening compounds therefor
EP4139001A4 (de) * 2020-04-23 2024-05-15 Georgetown University Kombinationstherapie aus artemisinin-verwandten verbindungen und histondeacetylasehemmern zur behandlung von hpv-verwandten gutartigen, prämalignen und malignen erkrankungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
EP0827742A1 (de) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Verwendung von Histondeacetylasehemmern zur Behandlung von Fibrose oder Zirrhose
US6124495A (en) * 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof

Also Published As

Publication number Publication date
EP1249246B1 (de) 2005-09-28
EP1249246A1 (de) 2002-10-16
WO2002083173A1 (en) 2002-10-24
US20040132817A1 (en) 2004-07-08
ATE305297T1 (de) 2005-10-15
DE60113645T2 (de) 2006-07-06

Similar Documents

Publication Publication Date Title
Tomaić Functional roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites
DE60113645D1 (de) Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten
Bodily et al. Human papillomavirus E7 enhances hypoxia-inducible factor 1–mediated transcription by inhibiting binding of histone deacetylases
Altamura et al. Transforming properties of Felis catus papillomavirus type 2 E6 and E7 putative oncogenes in vitro and their transcriptional activity in feline squamous cell carcinoma in vivo
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
DE69925268D1 (de) Dipeptid kaspase inhibitoren und deren verwendung
O'Connell et al. Interferon‐γ sensitizes colonic epithelial cell lines to physiological and therapeutic inducers of colonocyte apoptosis
EA200601239A1 (ru) Замещённые хинолиновые соединения
Minashima et al. Lithium protects against cartilage degradation in osteoarthritis
EA199900769A1 (ru) N-гидрокси-2-(алкил-, арил- или гетероарилсульфанил, -сульфинил или -сульфонил)-3-замещенные алкилов, арилов или гетероариламидов в качестве ингибиторов матриксных металлопротеиназ
EA199900669A1 (ru) Промежуточные соединения для получения замещенных n-[аминоиминометил или аминометил)фенил]пропиламидов
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE399012T1 (de) Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
Mallari et al. Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB
NO972538L (no) Nye sulfonamider
EA200400026A1 (ru) Ингибиторы вич-протеазы, содержащие их композиции, их фармацевтические применения и вещества для их синтеза
BRPI0409109A (pt) novos compostos
CY1109328T1 (el) Ενωσεις θειενοδιβενζοαζουλενιου ως αναστολεις παραγοντα νεκρωσης ογκου
JOP20220152A1 (ar) مشتقات 3-(5- ميثوكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخداماتها
CN106138018B (zh) 羟基二苯甲酮在制备抗病毒和抗肿瘤药物中的应用
Lin et al. Diallyl disulfide (DADS) induces apoptosis in human cervical cancer Ca Ski cells via reactive oxygen species and Ca2+-dependent mitochondria-dependent pathway
ES2151600T3 (es) Derivados de n-(3-amino-2-hidroxibutil)sulfonamida utilizados como inhibidores de proteasa de vih.
BRPI0411085A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de vìrus oncogênicos, e de condições ou distúrbios devidos a infecção por hpv
PT1071704E (pt) Novos inibidores e reguladores negativos das metaloproteinases da matriz
EA200400708A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee